Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess, whether the administration of a proton pump
inhibitor, Rabeprazole, has a negative effect on the activity of a concomitantly administered
blood thinner drug. Proton pump inhibitors (PPI's) are prescribed for patients with gastric
problems to reduce the gastric acid secretion. The blood thinner drug, Clopidogrel,
administered in this trial is approved for the treatment of mild heart attacks; it works by
preventing blood platelets from sticking together to form clots that would restrict blood
flow. Previous trials have shown that the proton pump inhibitor omeprazole interacts with the
blood thinning drug clopidogrel to reduce the active form of clopidogrel, thereby preventing
the drug's blood thinning effect. In this trial, the effect of two different proton pump
inhibitors, namely rabeprazole and omeprazole on the activity of the blood thinner drug
clopidogrel will be assessed and compared to the effect of placebo on the activity of the
blood thinner drug clopidogrel. This will be done in three sequential periods and each of the
patients enrolled into this trial will be asked to participate in three different periods,
during which clopidogrel with either rabeprazol, or omeprazol, or placebo will be
administered daily.